The Role of Epigenetics in T-cell Lymphoma

Overview

Journal Int J Hematol

Specialty Hematology

Date 2022 Oct 14

PMID 36239901

Authors

Makoto Yamagishi

Affiliations

Soon will be listed here.

Abstract

Malignant lymphomas are a group of diseases with epigenomic abnormalities fundamental to pathogenesis and pathophysiology. They are characterized by a high frequency of abnormalities related to DNA methylation regulators (DNMT3A, TET2, IDH2, etc.) and histone modifiers (EZH2, HDAC, KMT2D/MLL2, CREBBP, EP300, etc.). These epigenomic abnormalities directly amplify malignant clones. They also originate from a hematopoietic stem cell-derived cell lineage triggered by epigenomic changes. These characteristics are linked to their high affinity for epigenomic therapies. Hematology has led disease epigenetics in the areas of basic research, clinical research, and drug discovery. However, epigenomic regulation is generally recognized as a complex system, and gaps exist between basic and clinical research. To provide an overview of the status and importance of epigenomic abnormalities in malignant lymphoma, this review first summarizes the concept and essential importance of the epigenome, then outlines the current status and future outlook of epigenomic abnormalities in malignant lymphomas.

Citing Articles

Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.

Pichler A, Amador C, Fujimoto A, Takeuchi K, de Jong D, Iqbal J Histopathology. 2024; 86(1):119-133.

PMID: 39679758 PMC: 11648357. DOI: 10.1111/his.15376.

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.

Zain J, Tsai N, Palmer J, Simpson J, Adhikarla V, Bading J Blood Adv. 2024; 8(18):4812-4822.

PMID: 38838232 PMC: 11415869. DOI: 10.1182/bloodadvances.2023012497.

Therapeutic challenges in peripheral T-cell lymphoma.

Luan Y, Li X, Luan Y, Luo J, Dong Q, Ye S Mol Cancer. 2024; 23(1):2.

PMID: 38178117 PMC: 10765866. DOI: 10.1186/s12943-023-01904-w.

Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.

Yadav M, Uikey B, Rathore S, Gupta P, Kashyap D, Kumar C Front Oncol. 2023; 13:1235711.

PMID: 37746258 PMC: 10513393. DOI: 10.3389/fonc.2023.1235711.

Epigenetic targets in B- and T-cell lymphomas: latest developments.

Ribeiro M, Sanchez Vinces S, Mondragon L, Roue G Ther Adv Hematol. 2023; 14:20406207231173485.

PMID: 37273421 PMC: 10236259. DOI: 10.1177/20406207231173485.

References

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Rosen M . EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-92. PMC: 3681809. DOI: 10.1016/j.ccr.2013.04.011. View

Falchi L, Ma H, Klein S, Lue J, Montanari F, Marchi E . Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2020; 137(16):2161-2170. DOI: 10.1182/blood.2020009004. View

OConnor O, Falchi L, Lue J, Marchi E, Kinahan C, Sawas A . Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019; 134(17):1395-1405. DOI: 10.1182/blood.2019001285. View

Shen X, Liu Y, Hsu Y, Fujiwara Y, Kim J, Mao X . EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. 2008; 32(4):491-502. PMC: 2630502. DOI: 10.1016/j.molcel.2008.10.016. View

Yamagishi M, Suzuki Y, Watanabe T, Uchimaru K . Clonal Selection and Evolution of HTLV-1-Infected Cells Driven by Genetic and Epigenetic Alteration. Viruses. 2022; 14(3). PMC: 8950914. DOI: 10.3390/v14030587. View

Weinberg D, Papillon-Cavanagh S, Chen H, Yue Y, Chen X, Rajagopalan K . The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. Nature. 2019; 573(7773):281-286. PMC: 6742567. DOI: 10.1038/s41586-019-1534-3. View

Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A . Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012; 21(1):121-35. DOI: 10.1016/j.ccr.2011.12.015. View

Jones P, Issa J, Baylin S . Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016; 17(10):630-41. DOI: 10.1038/nrg.2016.93. View

Kondo Y, Shen L, Cheng A, Ahmed S, Boumber Y, Charo C . Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40(6):741-50. DOI: 10.1038/ng.159. View

10.

Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J . Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021; 112(9):3627-3635. PMC: 8409398. DOI: 10.1111/cas.15040. View

11.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Wang C, McKeithan T, Gong Q, Zhang W, Bouska A, Rosenwald A . IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015; 126(15):1741-52. PMC: 4600014. DOI: 10.1182/blood-2015-05-644591. View

14.

Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K . Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014; 4:e264. PMC: 4315889. DOI: 10.1038/bcj.2014.83. View

15.

Piekarz R, Robey R, Zhan Z, Kayastha G, Sayah A, Abdeldaim A . T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004; 103(12):4636-43. DOI: 10.1182/blood-2003-09-3068. View

16.

Qu K, Zaba L, Satpathy A, Giresi P, Li R, Jin Y . Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. Cancer Cell. 2017; 32(1):27-41.e4. PMC: 5559384. DOI: 10.1016/j.ccell.2017.05.008. View

17.

Lea Schumann F, Gross E, Bauer M, Rohde C, Sandmann S, Terziev D . Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. Biomedicines. 2021; 9(12). PMC: 8698684. DOI: 10.3390/biomedicines9121842. View

18.

Sneeringer C, Scott M, Kuntz K, Knutson S, Pollock R, Richon V . Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A. 2010; 107(49):20980-5. PMC: 3000297. DOI: 10.1073/pnas.1012525107. View

19.

Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y . Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014; 46(2):171-5. DOI: 10.1038/ng.2872. View

20.

Yamagishi M, Fujikawa D, Watanabe T, Uchimaru K . HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia-Lymphoma. Front Microbiol. 2018; 9:1686. PMC: 6066519. DOI: 10.3389/fmicb.2018.01686. View